Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited has announced that its product, Nimodipine, has received approval from the National Medical Products Administration of China to be marketed as a bulk drug. This development marks a significant step in the company’s product offerings, potentially enhancing its market position and providing new opportunities for growth in the pharmaceutical sector.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of drugs. The company is involved in creating treatments for various medical conditions, including ischemic cerebrovascular disease and hypertension.
YTD Price Performance: -0.47%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.25B
For detailed information about 2005 stock, go to TipRanks’ Stock Analysis page.